Global CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025 Report Highlights:
In the realm of oncology, the contribution of CD39 to immune suppression within the tumor microenvironment (TME) is well-established. Tumors frequently utilize the CD39-CD73-adenosine axis to evade immune surveillance, resulting in immune cell exhaustion and diminished anti-tumor responses. Elevated levels of CD39 on regulatory T cells (Tregs) and CD8+ T cells have been associated with unfavorable prognoses in various malignancies. By employing monoclonal antibodies that target CD39, such as IPH5201, it is possible to reactivate the immune system to more effectively combat tumor cells. IPH5201, which is being developed by Innate Pharma and AstraZeneca, is currently under investigation in conjunction with immune checkpoint inhibitors (ICIs) to enhance the immune response in patients with solid tumors.
In addition to cancer, CD39-targeting therapies show considerable potential for addressing other diseases, particularly chronic viral infections, autoimmune disorders, and sepsis. In the context of chronic infections like HIV, tuberculosis, and Chagas disease, CD39 is implicated in immune exhaustion and suppression, which obstructs effective immune responses. By inhibiting CD39, there is a possibility of reversing immune dysfunction and improving the body’s capacity to eliminate pathogens. In autoimmune disorders, where there is an overactivation of the immune system, the targeting of CD39 may aid in reestablishing equilibrium by enhancing the inhibitory function of regulatory T cells, which are vital for averting tissue damage.
The therapeutic promise of targeting CD39 also encompasses sepsis, as CD39 expression on monocytes and macrophages is instrumental in regulating inflammation. In the context of sepsis, achieving a balanced immune response is crucial to mitigate tissue injury while effectively managing infection. By inhibiting the activity of CD39, therapeutic interventions could diminish excessive inflammation and restore immune homeostasis, presenting a novel strategy for addressing this critical condition.
The clinical advancement of therapies aimed at CD39 is still in its nascent phase, with several candidates progressing through clinical trials, particularly in Phase 2. Among these, IPH5201 stands out as a leading candidate, demonstrating encouraging outcomes in both preclinical and early-phase clinical investigations. These antibodies are being assessed not only in oncology but also across a range of chronic conditions where CD39 plays a significant role in immune regulation. By focusing on CD39, these therapies seek to bolster immune responses in scenarios characterized by immune suppression or dysfunction.
Looking forward, the potential uses of CD39-targeting therapies are extensive. The integration of anti-CD39 antibodies with other treatment modalities, such as immune checkpoint inhibitors or antiviral therapies, presents the opportunity for synergistic effects, thereby enhancing the immune response. Nonetheless, challenges persist, particularly concerning the context-dependent function of CD39 across various diseases and patient demographics. Achieving a precise balance between immune activation and suppression will be essential for the safe and effective implementation of these therapies. As clinical trials advance and additional data is collected, therapies targeting CD39 may emerge as a fundamental component of personalized medicine, effectively addressing various diseases through the precise and controlled modulation of immune responses.
Global CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025 Report Highlights:
- First CD39 Targeted Therapy Approval Expected By 2029
- CD39 Targeted Therapies In Clinical Trials: > 15 Therapies
- CD39 Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase
- CD39 Targeted Therapy Research and Development Trends By Indication
- CD39 Targeted Therapies Proprietary Technologies Platforms By Company
In the realm of oncology, the contribution of CD39 to immune suppression within the tumor microenvironment (TME) is well-established. Tumors frequently utilize the CD39-CD73-adenosine axis to evade immune surveillance, resulting in immune cell exhaustion and diminished anti-tumor responses. Elevated levels of CD39 on regulatory T cells (Tregs) and CD8+ T cells have been associated with unfavorable prognoses in various malignancies. By employing monoclonal antibodies that target CD39, such as IPH5201, it is possible to reactivate the immune system to more effectively combat tumor cells. IPH5201, which is being developed by Innate Pharma and AstraZeneca, is currently under investigation in conjunction with immune checkpoint inhibitors (ICIs) to enhance the immune response in patients with solid tumors.
In addition to cancer, CD39-targeting therapies show considerable potential for addressing other diseases, particularly chronic viral infections, autoimmune disorders, and sepsis. In the context of chronic infections like HIV, tuberculosis, and Chagas disease, CD39 is implicated in immune exhaustion and suppression, which obstructs effective immune responses. By inhibiting CD39, there is a possibility of reversing immune dysfunction and improving the body’s capacity to eliminate pathogens. In autoimmune disorders, where there is an overactivation of the immune system, the targeting of CD39 may aid in reestablishing equilibrium by enhancing the inhibitory function of regulatory T cells, which are vital for averting tissue damage.
The therapeutic promise of targeting CD39 also encompasses sepsis, as CD39 expression on monocytes and macrophages is instrumental in regulating inflammation. In the context of sepsis, achieving a balanced immune response is crucial to mitigate tissue injury while effectively managing infection. By inhibiting the activity of CD39, therapeutic interventions could diminish excessive inflammation and restore immune homeostasis, presenting a novel strategy for addressing this critical condition.
The clinical advancement of therapies aimed at CD39 is still in its nascent phase, with several candidates progressing through clinical trials, particularly in Phase 2. Among these, IPH5201 stands out as a leading candidate, demonstrating encouraging outcomes in both preclinical and early-phase clinical investigations. These antibodies are being assessed not only in oncology but also across a range of chronic conditions where CD39 plays a significant role in immune regulation. By focusing on CD39, these therapies seek to bolster immune responses in scenarios characterized by immune suppression or dysfunction.
Looking forward, the potential uses of CD39-targeting therapies are extensive. The integration of anti-CD39 antibodies with other treatment modalities, such as immune checkpoint inhibitors or antiviral therapies, presents the opportunity for synergistic effects, thereby enhancing the immune response. Nonetheless, challenges persist, particularly concerning the context-dependent function of CD39 across various diseases and patient demographics. Achieving a precise balance between immune activation and suppression will be essential for the safe and effective implementation of these therapies. As clinical trials advance and additional data is collected, therapies targeting CD39 may emerge as a fundamental component of personalized medicine, effectively addressing various diseases through the precise and controlled modulation of immune responses.
1. INTRODUCTION TO CD39 TARGETING THERAPIES
1.1 Overview
1.2 Role of CD39 & Emergence As Therapeutic Target
1.3 Discovery of CD39 & Development Of Targeting Therapies
2. CD39 TARGETING THERAPIES MECHANISM OF ACTION
2.1 CD39 Inhibition
2.2 CD39 Agonism
3. CURRENT CD39 TARGETING THERAPY APPROACHES
3.1 Antibodies
3.2 Nucleic Acid Therapeutics
3.3 Small Molecule Inhibitors
4. GLOBAL CD39 TARGETED THERAPIES CLINICAL TRIALS OVERVIEW
4.1 By Company
4.2 By Indication
4.3 By Country
4.4 By Phase
5. CD39 TARGETED THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase II
6. GLOBAL CD39 TARGETING THERAPY MARKET TRENDS & DEVELOPMENTS
6.1 Current Market Outline
6.2 Future Market Opportunities
7. ROLE OF CD39 TARGETING THERAPIES BY INDICATION: CLINICAL DEVELOPMENT & COLLABORATIONS
7.1 Cancer
7.2 Autoimmune & Inflammatory Diseases
7.3 Cardiovascular Diseases
7.4 Infections
8. CD39 TARGETED THERAPIES TECHNOLOGY PLATFORMS
8.1 OligoCreator & LNAplus Platforms - Secarna Pharmaceuticals
8.2 Unnamed Platforms – Biotheus
8.3 Unnamed Platform - Adimab
8.4 OriAb Antibody Discovery Platform - Oricell Therapeutics
8.5 TMAb Platform - Sensei Biotherapeutics
9. GLOBAL CD39 TARGETED THERAPIES MARKET DYNAMICS
9.1 Market Drivers & Opportunities
9.2 Market Challenges & Restraints
10. COMPETITIVE LANDSCAPE
10.1 Adimab
10.2 Arcus Biosciences
10.3 Biotheus
10.4 BrightPath Biotherapeutics
10.5 Elpiscience Biopharmaceuticals
10.6 Innate Pharma
10.7 Orega Biotech
10.8 OriCell Therapeutics
10.9 Secarna Pharmaceuticals
10.10 Trishula Therapeutics
1.1 Overview
1.2 Role of CD39 & Emergence As Therapeutic Target
1.3 Discovery of CD39 & Development Of Targeting Therapies
2. CD39 TARGETING THERAPIES MECHANISM OF ACTION
2.1 CD39 Inhibition
2.2 CD39 Agonism
3. CURRENT CD39 TARGETING THERAPY APPROACHES
3.1 Antibodies
3.2 Nucleic Acid Therapeutics
3.3 Small Molecule Inhibitors
4. GLOBAL CD39 TARGETED THERAPIES CLINICAL TRIALS OVERVIEW
4.1 By Company
4.2 By Indication
4.3 By Country
4.4 By Phase
5. CD39 TARGETED THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase II
6. GLOBAL CD39 TARGETING THERAPY MARKET TRENDS & DEVELOPMENTS
6.1 Current Market Outline
6.2 Future Market Opportunities
7. ROLE OF CD39 TARGETING THERAPIES BY INDICATION: CLINICAL DEVELOPMENT & COLLABORATIONS
7.1 Cancer
7.2 Autoimmune & Inflammatory Diseases
7.3 Cardiovascular Diseases
7.4 Infections
8. CD39 TARGETED THERAPIES TECHNOLOGY PLATFORMS
8.1 OligoCreator & LNAplus Platforms - Secarna Pharmaceuticals
8.2 Unnamed Platforms – Biotheus
8.3 Unnamed Platform - Adimab
8.4 OriAb Antibody Discovery Platform - Oricell Therapeutics
8.5 TMAb Platform - Sensei Biotherapeutics
9. GLOBAL CD39 TARGETED THERAPIES MARKET DYNAMICS
9.1 Market Drivers & Opportunities
9.2 Market Challenges & Restraints
10. COMPETITIVE LANDSCAPE
10.1 Adimab
10.2 Arcus Biosciences
10.3 Biotheus
10.4 BrightPath Biotherapeutics
10.5 Elpiscience Biopharmaceuticals
10.6 Innate Pharma
10.7 Orega Biotech
10.8 OriCell Therapeutics
10.9 Secarna Pharmaceuticals
10.10 Trishula Therapeutics
